# An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

> **NCT05562934** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 189 (actual)

## Conditions studied

- Resistant Hypertension

## Interventions

- **BIOLOGICAL:** XXB750 drug
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05562934
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-08
- **Primary completion:** 2024-07-02
- **Final completion:** 2024-08-27
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05562934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05562934, "An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05562934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*